Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Thai Foreign Minister Laments Placement On U.S. ‘Priority Watch List”

This article was originally published in PharmAsia News

Executive Summary

Thailand's foreign minister said he was disappointed the United States decided to keep the country on its "priority watch list" of nations considered to have intellectual property rights protection issues. The minister did not mention the concerns of the United States regarding Thailand's compulsory licensing law targeting some foreign-made pharmaceuticals. Instead, he focused on the cooperation Thailand has given the United States in the area of stiffening actions against intellectual property piracy. The Office of U.S. Trade Representative said it remained concerned about the outcome of Thailand's compulsory licensing policy related to some foreign-made drugs. A USTR report said the agency is waiting to see if the new government retains the CL policy of the previous regime. (Click here for more

Latest Headlines
See All
UsernamePublicRestriction

Register

SC068327

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel